Victrex saw sales volumes slow down in the second half of 2012

On Tuesday morning high performance polymer manufacturer Victrex announced that annual group profit before tax increased to 94.5m pounds, marginally above year ago levels, much the same as its basic earnings per share of 85.7p.

On Tuesday morning high performance polymer manufacturer Victrex announced that annual group profit before tax increased to 94.5m pounds, marginally above year ago levels, much the same as its basic earnings per share of 85.7p.

That as sales volumes at its main Victrex Polymer Solutions (VPS) business progressed at a lower run-rate than in the record second half of last financial year. Thus, group revenue rose by just 2% to £219.8m for the year ending on September 30th 2012.

Amongst the company's products are the polymer-based pipe system for the cargo drainage system on the Airbus A350 XWB line of passenger jets. The company's other main product line, Invibio, provides access to highly specialized biocompatible (can be used within the human body) materials and services for medical device manufacturers.

Full year gross margin remained in line with the company's own expectations, at 66.3%, but came in below last year's level of 67.8%.

Earnings benefitted nonetheless from an improvement in the effective tax rate to 23.9%, predominantly reflecting the reduction in the UK corporation tax rate.

The company had cash of £83.9m and no debt at the end of the financial year.

Chairman confident on outlookCommenting on the results Chairman Anita Frew said: "(...) Sales volume in our VPS business is showing good growth relative to the comparative period last year, albeit at a lower run rate than the record second half of last financial year. Our Invibio business has had a steady start to the year despite the continuing challenges in the US medical device market.

"Whilst it is early in the financial year, and a number of macro uncertainties remain, we are encouraged by the potential for growth in both VPS, driven by new application development, and Invibio, through innovation in the spine market and further progress in our developing markets (...)," she added.

The company's Board of Directors has recommended an increase in the full year dividend of 15% to 37.4p (2011: 32.5p), resulting in a final dividend of 28.4p (2011: 24.5p) per ordinary share.

The dividend cover will thus be reduced to 2.3 times, from last year's level of 2.6 times.

At 09:24, the share price of Victrex was down 3.36% to 1,581p, after yesterday hitting an intraday 52 week high above 1,650p.

MF

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022